Document Detail

Autologous cell therapies: challenges in US FDA regulation.
MedLine Citation:
PMID:  23210819     Owner:  NLM     Status:  In-Data-Review    
Cell-based therapies (CBTs) have been hailed for the last two decades as the next pillar of healthcare, yet the clinical and commercial potential of regenerative medicine has yet to live up to the hype. While recent analysis has suggested that regenerative medicine is maturing into a multibillion dollar industry, examples of clinical and commercial success are still relatively rare [1-3] . With 30 years of laboratory and clinical efforts fueled by countless billions in public and private funding, one must contemplate why CBTs have not made a greater impact. The current regulatory environment, with its zero-risk stance, stymies clinical innovation while fueling a potentially risky medical tourism industry. Here, we highlight the challenges the US FDA faces and present talking points for an improved regulatory framework for autologous CBTs.
Todd N McAllister; David Audley; Nicolas L'heureux
Related Documents :
23866659 - Practicing like thomas edison.
10423779 - Management factors associated with babesia bovis seroprevalence in cattle from eastern ...
25116569 - Sharps practice in focus.
24278809 - Globalization of healthcare.
20546989 - Effectiveness of percutaneous vesico-amniotic shunting in congenital lower urinary trac...
1161039 - Critical species, including man, within the biosphere.
22043729 - Revisit, revamp and revitalize your business plan: part 4.
15533149 - Quality of life following microsurgery, radiosurgery and conservative management for un...
20092449 - Priapism: pathogenesis, epidemiology, and management.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Regenerative medicine     Volume:  7     ISSN:  1746-076X     ISO Abbreviation:  Regen Med     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-12-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101278116     Medline TA:  Regen Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  94-7     Citation Subset:  IM    
Cytograft Tissue Engineering, Inc., 3 Hamilton Landing, Suite 220, Novato, CA 94949, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cell standardization: purity and potency.
Next Document:  Autologous cell therapies: the importance of regulatory oversight.